TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: number of functional limitations post COVID-19
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: rate of first shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of arrhythmic syncope
Endpoint domain: Adverse events/effects
Primary endpoint: Mean NT-proBNP level (or BNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different functional classes of CHF according to NYHA classification based on patient symptoms of HF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Difference Between Post-Methylphenidate and Post-Placebo Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titer (GMT) of Human Papillomavirus (HPV) Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Bactericidal Assay Using Human Complement (hSBA) GMTs of PMB80 [A22] and PMB2948 [B24]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sirt1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in vascular health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Systemic Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Progression of Thyroid Papillary Microcarcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: recurrent ischemic strokes
Endpoint domain: Mortality/survival
Primary endpoint: Reproducibility of RFCSA measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual stenosis in the lesion(s) treated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pneumococcal carriage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: invasiveness of emerging replacement carriage serotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of participants applying evidence
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Level of anti band 3 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in Maximum Ashworth Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Global Impression of Change (PGIC) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient satisfaction with the nurse-patient relation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnosis of Autism Spectrum Disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late postoperative endpoint of 4 MACE complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: subclinical diastolic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose of imatinib mesylate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Summed mass of growth hormone over 10 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adhesion Free at Sites of Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Pain Assessment
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: World Health Organization Quality of Life (WHOQOL-BREF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Waist to Hip Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability Assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Probability of dose escalation based on true dose limiting toxicity (DLT) rate
Endpoint domain: Adverse events/effects
Primary endpoint: D-dimer change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in brain response to pain stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Disease-free or death-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in the Psoriasis Area and Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-matched change from baseline in QTcI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum lipoprotein concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exercise-induced pulmonary hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 2 Year Progression-free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Serum lamotrigine Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum lamotrigine AUC(0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of DCVS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Efficacy of BOTOX in treating OAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Optimal Tolerated Regimen (OTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of WLE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic performance of NBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recurrent adenoma - histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants Who Complete Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Completing Homework Assignment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in blood flow in hepatic artery and main portal vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dyskinesia Severity AUC Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change from baseline scores of the Progressive Supranuclear Palsy Rating Scale (PSPRS) at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of the Schwab and England Activities of Daily Living Scale (SEADL) at 52 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Treatment response to Sacubitril-Valsartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Metabolic profiles of JNJ-53718678
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Timed up and go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Trail Making Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Emotional dot probe
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete Cure of Blepharitis Signs and Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Change From Baseline in Tear Break-up Time (TBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Faslodex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Vascular Inflammation of the Aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in Cardiometabolic Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine concentration of testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of participants with NRM and Grade III-IV acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of palliative sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of patients reporting no headache pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of patients having absence of most bothersome migraine-associated symptom (MBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of patients who have sustained pain freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conjunctival Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse reactions incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of mortality within 28-days
Endpoint domain: Mortality/survival
Primary endpoint: Time to clinical improvement on a seven-category ordinal scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in disease control (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Esophageal Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of deaths or major vascular events
Endpoint domain: Mortality/survival
Primary endpoint: Biochemical or clinical progression-free survival at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Resting and Post-Stressor Fibrinolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral and lower extremity vasomotor reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nitric oxide biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fasting insulin, HOMA-IR, post-load insulin response, glucose tolerance, insulin sensitivity, insulin signaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Preoperative measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of compliance with federal recommendations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Headache Impact Test (HIT-6) total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ketone Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of confirmed COVID-19 cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: reflectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peroperative remifentanil consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in Muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Intraoperative Time Body Temperature Above 36 Degrees Celsius
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-extubation stridor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Surgeon Satisfaction Rating Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of neonates with confirmed deletion of 2 copies of SMN1 gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Genetic outcomes
Primary endpoint: tissue tolerance of the breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Treatment-related toxicity event rate
Endpoint domain: Adverse events/effects
Primary endpoint: evolution of phobic fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: investigator's global assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tactile sensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: pharmacokinetics of piperacillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in CSF Levels of Tau
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in CSF Levels of Amyloid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Brief Observation of Social Communication Change (BOSCC) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CD4 Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants That Experience Acute Haploidentical Alpha Beta Depleted Transplant (aGVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants That Experience Chronic Haploidentical Alpha Beta Depleted Transplant (cGVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: TFVdp/FTCtp concentrations in ectocervical/vaginal tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TFVdp/FTCtp concentrations in rectal tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TFVdp/FTCtp concentrations in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TFVdp/FTCtp concentrations in seminal mononuclear cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment related adverse events grade >2
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of artifacts in 4DCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications post-TIPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Vision Loss to 20/40 or Worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glycemic threshold for hypothalamic activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Patients with ACap™ Confirm Algorithm Programmed Safely to ON
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation-induced lung toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent of change in brachial artery dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BOLD Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCo-inf of plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of plasma GK Activator (2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of urine GK Activator (2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SANDE Questionnaire Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in Lissamine Green Conjunctival Staining Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: 24-hour Pulse Wave Velocity (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-hour Augmentation Index (AI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-hour Central Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patients' satisfaction of PREVENT tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Provider's satisfaction of PREVENT tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fidelity of PREVENT tool implementation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to first confirmed perceptible pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of acute grade 3-5 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with dermatological disorders due to iron overload
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Advanced adenoma or cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Craving Questionnaire Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Cigarettes Smoked Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Postoperative Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Speed of hand movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement in diagnoses between ECG methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of freezing of gait events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time taken to achieve adequacy of sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exposure to fluoroscopic radiation
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events associated with NAFR treatment
Endpoint domain: Adverse events/effects
Primary endpoint: case occurrence of multiple sclerosis
Endpoint domain: Mortality/survival
Primary endpoint: Dyspepsia symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of time with bispectral index between 40 and 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coparenting Quality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Assessment of tensor fascia latae muscle on shear wave elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Assessment of gluteus medius muscle on shear wave elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Assessment of iliotibial band on shear wave elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Dose limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Safety analysis of combination regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Lumbar flexion range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Mental Health Questionnaire (PMHQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychological Vulnerability Scale (PVS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety information of palonosetron hydrochloride capsules
Endpoint domain: Adverse events/effects
Primary endpoint: Composite pulmonary hypertension detection score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual Acuity - High Contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Acuity - Low Contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Response on Facemask Usability Questionnaire - Overall Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feasibility of OCT measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trans-tracheal Pressure Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cortical GABA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Discussions Related to the Geriatric Assessment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Patient Satisfaction With Communication About Age-related Concerns
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Observed Serum Concentration (Cmax) of AMG 592
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Observed Concentration (tmax) of AMG 592
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration-time Curve to the Last Measurable Point (AUClast) of AMG 592
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes